
Quarterly report 2025-Q3
added 11-06-2025
Athira Pharma Market Cap 2011-2026 | ATHA
As of March 22, 2026 Athira Pharma has a market cap of $ 269 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Athira Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.2 M | 150 M | 98.9 M | 338 M | 161 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 338 M | 16.2 M | 153 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
308 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Galera Therapeutics
GRTX
|
7.65 M | - | -32.59 % | $ 7.61 M | ||
|
Pharming Group N.V.
PHAR
|
5.94 B | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Kamada Ltd.
KMDA
|
271 M | $ 8.5 | -1.39 % | $ 260 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Benitec Biopharma
BNTC
|
556 M | $ 10.98 | -4.52 % | $ 452 M | ||
|
Inventiva S.A.
IVA
|
535 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Compugen Ltd.
CGEN
|
196 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
81.3 M | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
948 K | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Foghorn Therapeutics
FHTX
|
356 M | $ 5.0 | 2.25 % | $ 315 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
AbCellera Biologics
ABCL
|
962 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Curis
CRIS
|
13.2 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
226 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Cellectis S.A.
CLLS
|
203 M | $ 3.34 | -4.02 % | $ 116 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.24 | -2.97 % | $ 704 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 1.8 | -1.1 % | $ 120 M | ||
|
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | ||
|
Cabaletta Bio
CABA
|
20.5 M | $ 2.94 | -3.29 % | $ 3.43 M | ||
|
Iterum Therapeutics
ITRM
|
28 M | $ 0.16 | -5.45 % | $ 3.15 M | ||
|
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M |